ArticleEuropean journal of neurology2025
Clinical and Genetic Characterization of the Largest Cohort of Patients With D3 Limb-Girdle Muscular Dystrophy in an Isolated Uruguayan Population.
Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical and Genetic Characterization of the Largest Cohort of Patients With D3 Limb-Girdle Muscular Dystrophy in an Isolated Uruguayan Population.European journal of neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundLimb-girdle muscular dystrophies (LGMD) are a heterogeneous group of genetic disorders characterized by progressive proximal weakness. LGMD D3 is an extremely rare autosomal dominant myopathy caused by pathogenic variants in the HNRNPDL gene encoding a protein related to RNA processing. To date, only six countries and seven families have been reported worldwide: Brazil, China and Italy with the pathogenic variant c.1132G>A p.(Asp378Asn), Uruguay, Argentina and Spain with the pathogenic variant c.1132G>C p.(Asp378His).
methodsThe study was conducted in the city of Nueva Palmira in Uruguay between March 2019 to August 2024. Forty-nine patients with LGMD D3 and 10 asymptomatic individuals carrying the mutation were examined. Serum CK, electromyography, MRI, and pulmonary function testing results were reviewed when available. Whole exome sequencing and screening test for the mutation were performed. Statistical analysis was done using STATA 16.1.
resultsLGMD D3 in Uruguay presents as a slowly progressive adult-onset scapulo-pelvic-peroneal dystrophy. Pathogenic variant c.1132G>C p.(Asp378His) was confirmed in all participants. Estimated prevalence of LGMD D3 was 3.75/1000 in Nueva Palmira. Mean age of onset differed by sex, with men presenting younger (p = 0.006). Characteristic MRI features were observed.
conclusionsLGMD D3 presents with a distinctive scapulo-pelvic-peroneal phenotype. To our knowledge, this is the largest LGMD D3 cluster and the first report of sex-dependent age of onset. Our study illustrates how genetic isolation can lead to high LGMD D3 prevalence in an admixed population and explores its potential origin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.